APO Research
Talk to an analyst

APO RESEARCH · REPORT

T-Cell & NK-Cell Engaging Bispecific Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Outlook and Growth Opportunities 2026

29 December 2025193 pages

Choose your research edition.

Industry ResearchT-Cell & NK-Cell Engaging Bispecific Antibodies Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global T-Cell & NK-Cell Engaging Bispecific Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for T-Cell & NK-Cell Engaging Bispecific Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T-Cell & NK-Cell Engaging Bispecific Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T-Cell & NK-Cell Engaging Bispecific Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the T-Cell & NK-Cell Engaging Bispecific Antibodies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the T-Cell & NK-Cell Engaging Bispecific Antibodies market include Immunocore, MacroGenics, Regeneron, AbbVie, Amgen, Pfizer, Roche and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global T-Cell & NK-Cell Engaging Bispecific Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T-Cell & NK-Cell Engaging Bispecific Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T-Cell & NK-Cell Engaging Bispecific Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the T-Cell & NK-Cell Engaging Bispecific Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Company

Immunocore

MacroGenics

Regeneron

AbbVie

Amgen

Pfizer

Roche

Johnson & Johnson

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Type

T-Cell Engagers

NK-Cell Engagers

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Application

Hematological Cancers

Solid Tumors

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global T-Cell & NK-Cell Engaging Bispecific Antibodies status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions T-Cell & NK-Cell Engaging Bispecific Antibodies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify T-Cell & NK-Cell Engaging Bispecific Antibodies significant trends, drivers, influence factors in global and regions.

6. To analyze T-Cell & NK-Cell Engaging Bispecific Antibodies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T-Cell & NK-Cell Engaging Bispecific Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T-Cell & NK-Cell Engaging Bispecific Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T-Cell & NK-Cell Engaging Bispecific Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the T-Cell & NK-Cell Engaging Bispecific Antibodies market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global T-Cell & NK-Cell Engaging Bispecific Antibodies industry.

Chapter 3: Detailed analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of T-Cell & NK-Cell Engaging Bispecific Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of T-Cell & NK-Cell Engaging Bispecific Antibodies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends Table 2. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Drivers Table 3. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Opportunities and Challenges Table 4. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Restraints Table 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Company (2021-2026) Table 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Company (K Units) & (2021-2026) Table 8. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Company (2021-2026) Table 9. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Price (US$/Unit) of Company (2021-2026) Table 10. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Ranking, (2024-2026) & (USD Million) Table 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Key Company Manufacturing Base & Headquarters Table 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company, Product Type & Application Table 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of T-Cell Engagers Table 18. Significant Companies of NK-Cell Engagers Table 19. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Type (2021-2026) & (K Units) Table 21. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Type (2027-2032) & (K Units) Table 22. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Type (2021-2026) Table 23. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Type (2027-2032) Table 24. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type (2021-2026) Table 28. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hematological Cancers Table 30. Significant Companies of Solid Tumors Table 31. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Application (2021-2026) & (K Units) Table 33. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Application (2027-2032) & (K Units) Table 34. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Application (2021-2026) Table 35. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Application (2027-2032) Table 36. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application (2021-2026) Table 40. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application (2027-2032) Table 41. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2021-2026) & (K Units) Table 43. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region (2021-2026) Table 44. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2027-2032) & (K Units) Table 45. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region (2027-2032) Table 46. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Region (2021-2026) Table 49. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Region (2027-2032) Table 51. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2026) & (K Units) Table 56. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2021-2026) Table 57. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2027-2032) & (K Units) Table 58. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2027-2032) Table 59. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Market Share by Country (2021-2026) Table 61. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Market Share by Country (2027-2032) Table 63. Immunocore Company Information Table 64. Immunocore Business Overview Table 65. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 67. Immunocore Recent Development Table 68. MacroGenics Company Information Table 69. MacroGenics Business Overview Table 70. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 72. MacroGenics Recent Development Table 73. Regeneron Company Information Table 74. Regeneron Business Overview Table 75. Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 77. Regeneron Recent Development Table 78. AbbVie Company Information Table 79. AbbVie Business Overview Table 80. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 82. AbbVie Recent Development Table 83. Amgen Company Information Table 84. Amgen Business Overview Table 85. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 87. Amgen Recent Development Table 88. Pfizer Company Information Table 89. Pfizer Business Overview Table 90. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 92. Pfizer Recent Development Table 93. Roche Company Information Table 94. Roche Business Overview Table 95. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 97. Roche Recent Development Table 98. Johnson & Johnson Company Information Table 99. Johnson & Johnson Business Overview Table 100. Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 102. Johnson & Johnson Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors List Table 106. T-Cell & NK-Cell Engaging Bispecific Antibodies Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. T-Cell & NK-Cell Engaging Bispecific Antibodies Product Image Figure 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032) & (US$ Million) Figure 4. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (2021-2032) & (K Units) Figure 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. T-Cell Engagers Image Figure 10. NK-Cell Engagers Image Figure 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Type (2021-2032) Figure 14. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type (2021-2032) Figure 17. Hematological Cancers Image Figure 18. Solid Tumors Image Figure 19. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Application (2021-2032) Figure 22. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application (2021-2032) Figure 25. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032) & (US$ Million) Figure 30. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032) & (US$ Million) Figure 32. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032) & (US$ Million) Figure 36. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. T-Cell & NK-Cell Engaging Bispecific Antibodies Value Chain Figure 124. Manufacturing Cost Structure Figure 125. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • T-Cell Engagers
  • NK-Cell Engagers
Applications
  • Hematological Cancers
  • Solid Tumors
Companies covered
  • Immunocore
  • MacroGenics
  • Regeneron
  • AbbVie
  • Amgen
  • Pfizer
  • Roche
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032)
  4. 1.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume (2021-2032)
  5. 1.2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Dynamics
  1. 2.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends
  2. 2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Drivers
  3. 2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Opportunities and Challenges
  4. 2.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Restraints
3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Company
  1. 3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Revenue Ranking in 2025
  2. 3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Company (2021-2026)
  3. 3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Company (2021-2026)
  4. 3.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Price by Company (2021-2026)
  5. 3.5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Ranking (2024-2026)
  6. 3.6 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Manufacturing Base and Headquarters
  7. 3.7 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Product Type and Application
  8. 3.8 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 T-Cell & NK-Cell Engaging Bispecific Antibodies Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Type
  1. 4.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Type Introduction
  2. 4.1.1 T-Cell Engagers
  3. 4.1.2 NK-Cell Engagers
  4. 4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Type
  5. 4.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Type (2021-2032)
  7. 4.2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Type (2021-2032)
  8. 4.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Type
  9. 4.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Type (2021-2032)
  11. 4.3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type (2021-2032)
5 T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Application
  1. 5.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Application Introduction
  2. 5.1.1 Hematological Cancers
  3. 5.1.2 Solid Tumors
  4. 5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Application
  5. 5.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume by Application (2021-2032)
  7. 5.2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Volume Share by Application (2021-2032)
  8. 5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Application
  9. 5.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Application (2021-2032)
  11. 5.3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application (2021-2032)
6 T-Cell & NK-Cell Engaging Bispecific Antibodies Regional Sales and Value Analysis
  1. 6.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region: 2021-2026
  4. 6.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2027-2032)
  5. 6.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Region (2021-2032)
  7. 6.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Region: 2021-2026
  8. 6.4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Region (2027-2032)
  9. 6.5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032)
  12. 6.6.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032)
  15. 6.7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032)
  21. 6.9.2 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Country, 2025 VS 2032
7 T-Cell & NK-Cell Engaging Bispecific Antibodies Country-level Sales and Value Analysis
  1. 7.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2032)
  4. 7.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2026)
  5. 7.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2027-2032)
  6. 7.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Country (2021-2032)
  7. 7.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Country (2021-2026)
  8. 7.4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Immunocore
  2. 8.1.1 Immunocore Company Information
  3. 8.1.2 Immunocore Business Overview
  4. 8.1.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  6. 8.1.5 Immunocore Recent Developments
  7. 8.2 MacroGenics
  8. 8.2.1 MacroGenics Company Information
  9. 8.2.2 MacroGenics Business Overview
  10. 8.2.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  12. 8.2.5 MacroGenics Recent Developments
  13. 8.3 Regeneron
  14. 8.3.1 Regeneron Company Information
  15. 8.3.2 Regeneron Business Overview
  16. 8.3.3 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  18. 8.3.5 Regeneron Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Johnson & Johnson
  44. 8.8.1 Johnson & Johnson Company Information
  45. 8.8.2 Johnson & Johnson Business Overview
  46. 8.8.3 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  48. 8.8.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Value Chain Analysis
  2. 9.1.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Mode & Process
  6. 9.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors
  9. 9.2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst